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Objectives: We aimed to summarize the evidence examining factors that predict differential response to
mycophenolate mofetil (MMF) in systemic lupus erythematosus (SLE).
Methods: Systematic searches of randomized clinical trials (RCT) to identify predictors of the effects of
MMF (moderators), and cohort studies to explore prognostic factors associated with MMF outcomes
(response, relapse, or adverse events) were performed. Two reviewers independently assessed the
methodological quality of RCTs using the Cochrane Collaboration risk of bias tool and cohort studies
using the QUality In Prognosis Studies tool. The quality of subgroup analysis, providing evidence for
moderation, was evaluated. The Grading of Recommendations Assessment, Development, and Evaluation
working group approach summarized the quality of evidence (QoE), considering the risk of bias,
imprecision, inconsistency, indirectness, and publication bias.
Results: From 26 studies (13 from 7 RCTs and 13 cohort studies) we found low QoE evidence for Black/
Hispanic race/ethnicity predicting better renal responses to MMF in lupus nephritis (LN) from one RCT.
There was low QoE evidence from cohort studies that a higher baseline creatinine and membranous
features on renal biopsy were associated with poorer responses in LN. There was very low QoE for other
moderators or prognostic factors associated with MMF treatment outcomes. QoE from RCTs was affected
by exploratory or insufﬁcient evidence from subgroup analysis and in both study types high risk of bias,
indirectness and imprecision also affected QoE.
Conclusions: In SLE, evidence for predictors of response to MMF is limited and none can be recom-
mended for use in routine clinical practice. Speciﬁc studies of predictors measured at baseline and during
treatment are needed with a priori hypotheses based on preliminary evidence to date and with sufﬁcient
power to determine which factors can be employed in clinical decision making.
& 2017 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Personalized medicine is one of the emerging strategic plans of
clinicians, academics, and policy makers to improve treatment
outcomes in different conditions. The ability to identify subgroups
of patients prior to treatment that are most likely to experiencer HS Journals, Inc. This is an open
tre for Epidemiology, Centre
ation and Repair, Stopford
chester M13 9PT, UK.
Bruce).beneﬁt (or least likely to experience harm) could allow treatments
to be personalized, reduce health care costs, and accelerate the
development of new therapeutics [1].
Personalized medicine is particularly relevant in SLE; in spite of
current standard of care, 20–70% of patients with lupus nephritis
(LN) fail to achieve remission [2] and 10–15% of patients still
progress to end-stage renal disease within 10 years [3]. The
current mainstay of management of LN and moderate–severe
non-renal SLE is hydroxychloroquine, corticosteroids, and non-
speciﬁc immunosuppressive drugs in the majority of patients [4].
As such, identiﬁcation of those subgroups of patients withaccess article under the CC BY-NC-ND license
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ments would be of value to help physicians choose the “best
treatment” for each patient, and to improve treatment outcomes [1].
Recent guidelines suggested that mycophenolate mofetil (MMF)
can be considered a therapeutic option in patients with LN [5–7].
Randomized controlled trials (RCTs) show that MMF efﬁcacy is
similar to intravenous cyclophosphamide (IVC) in the induction
phase, and superior to azathioprine in the maintenance [8–10]. There
is also evidence suggesting that black and Hispanic patients are more
likely to achieve a renal response with MMF than with IVC induction
[8,11]. However, guidelines have not included MMF as a therapeutic
option for the management of non-renal lupus activity including
neuropsychiatric manifestations [12].
A wide range of factors may potentially predict the effects of
treatment on outcomes such as response, remission, or relapse in
SLE patients, including genetic [13], sociodemographic [11], clinical
[14,15], histopathological [16], and drug-related factors [15,17].
However, predictors (moderators) of the effects of MMF remain
poorly understood. In recent years, the importance of moderators
in testing the effectiveness of clinical interventions in RCTs has
become increasingly apparent [18]. Effect moderators represent
variables, for example, patient characteristics, measured at base-
line that interact with treatment to change outcome for speciﬁc
subgroups in RCTs. These specify for whom and under what
conditions treatment is most effective, and can improve power
in subsequent trials by better selection of target groups for
stratiﬁcation. Cohort studies may also provide exploratory evi-
dence of predictors of treatment outcomes [19], in two different
ways: (1) all participants are treated with MMF, but in this case it
will not be quite clear if the factor predicts response to MMF, or
would predict response regardless of treatment (i.e., it might “just”
be a prognostic factor) and (2) response to MMF is compared to
another type of treatment (as in a non-randomised trial). Such
studies may provide evidence for moderation (similar subgroup
analyses may be conducted as in trials), but of course, there is a
risk of confounding by indication, as there is no randomization.
To date some RCTs and cohort studies in SLE have evaluated
potential predictors of treatment response to MMF. The identi-
ﬁcation of potential moderators can, however, suffer seriously
from limitations such as the lack of an a priori, evidence-/
theoretical-based hypothesis, and the use of unreliable or invalid
measures of moderators [20]. In this regard, an assessment of the
risk of bias and validity of studies is required to provide an
adequate understanding of the strength of the evidence for
predictors of response to MMF. To the best of our knowledge, no
systematic review has aimed to address this question.
The objectives of this systematic review, therefore, were as
follows: (1) to identify predictors of differential response to MMF
treatment for SLE (effect moderators) in RCTs and (2) to identify
prognostic factors that are associated with clinical outcomes
following MMF treatment for SLE (outcome predictors) in obser-
vational cohorts.Methods
Literature search
We searched MEDLINE via Ovid (1946 to October 2015),
EMBASE via Ovid (1974 to October 2015), The Cochrane Central
Register of Randomized Controlled Trials (CENTRAL-The Cochrane
Library) via Ovid (to October 2015) and Web of Science (to October
2015). Additional hand-searches were carried out on the refer-
ences of selected studies. The search strategies used for Ovid
MEDLINEs and applied to other databases in the literature are
available in Table 1 (Supplementary File A). Only articles publishedin English, Spanish, and Italian were considered for inclusion. We
identiﬁed studies where the drug used was mycophenolic acid or
mycophenolate mofetil.Selection criteria
The articles were selected by two independent reviewers:
(C.M.P.) and (C.P.), who judged irrelevance of articles based on
their title and abstract. The inclusion criteria were as follows:
(1) RCTs and quasi-randomized studies in all different phases that
compared MMF versus control in SLE patients. RCTs were used to
identify those articles that included analysis of effect moderation,
for example, subgroup analysis. (2) Prospective or retrospective
cohort studies, which included a standardised assessment prior to
treatment and reported associations with MMF outcomes follow-
ing treatment. Observational studies were used to identify baseline
factors or those measured during the MMF treatments that were
associated with outcome (response, relapse/ﬂare, and adverse
events). Treatment outcomes were deﬁned as a signiﬁcantly
increased response/remission or relapse/ﬂares rates (according
the criteria deﬁned by each study author) or a greater decrease
of disease activity measured using any validated index
(Supplementary File A, Table 2). We also included adverse events
to retain a balance between the desirable and undesirable effects
of an intervention [21].
We excluded review articles, opinion papers, letters to the
editor, case reports, case series, or conference abstracts. Studies
reporting predictors of outcomes using MMF in as part of a
combination therapy, except for hydroxychloroquine (HCQ) or
corticosteroids were also excluded.Study screening
References and abstracts identiﬁed by the search were
imported into Reference Manager (RefMan) Version 12 and dupli-
cates were removed. Titles and abstracts were screened to remove
editorials, commentaries, and letters. The full text of each remain-
ing article was then tested against the inclusion and exclusion
criteria by two reviewers (C.M.P. and C.P.). The literature review
team also made every effort to identify multiple publications from
a single trial. Reason(s) for ineligibility were documented for all
studies excluded in the second phase of screening, using pre-
piloted form. Disagreements were resolved through discussion or
by a third reviewer (I.N.B. or B.P.) if necessary.Data extraction
Study details for RCTs: author identiﬁcation, year of publication,
setting, number of patients included, intervention, and control
treatment including dose and administration details, study dura-
tion, possible moderators or mediators, and relevant outcomes.
Study details for cohort studies: study design, setting, study
duration, number of patients included, age and gender of partic-
ipants, risk factors, relevant outcomes, and adjustment for con-
founders. Data extraction was done independently by two
reviewers. When available, subgroup effects or associations of
prognosis factors with MMF treatment outcome were extracted
from each published report. When there was insufﬁcient informa-
tion regarding estimates of associations or treatment effects in
original reports, where possible these were estimated using
methods recommended in the Cochrane Handbook for Systematic
Reviews of Interventions [22].
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Risk of bias in RCTs
We assessed study quality according to the PRISMA guidelines
[23]. For RCTs, the overall study quality was assessed using the
Cochrane Collaboration’s risk of bias tool using the following
domains: sequence generation, allocation concealment, blinding
performance, incomplete outcome data, selective outcome report-
ing, and other sources of bias [24]. The purpose of the quality
appraisal was to describe the QoE, relevant studies not to include
or excluded based on quality. Each domain was rated as adequate,
inadequate or unclear risk of bias. Where a study had multiple
publications, risk of bias assessment was conducted on the article
containing the main study ﬁndings. Two reviewers (C.M.P. and
C.P.) independently rated the methodological quality of the
selected studies. The two reviewers discussed disagreement about
whether a criterion was met, and resolved by consensus.
Quality of subgroup analyses
Due to the lack of an established standard for assessing the
quality of studies with subgroup (moderation) analyses we used
the following criteria, based on guidance from the Cochrane
handbook and a consensus study of international experts [20].(1) Was the subgroup analysis speciﬁed a priori?
(2) Was the selection of subgroup factors for analysis theory/
evidence driven?
(3) Were subgroup factors measured prior to randomization?
(4) Was measurement of subgroup factors measured by adequate
(reliable and valid) measurements, appropriate for the target
population?(5) Does the analysis contain an explicit test of the interaction
between moderator and treatment?We classiﬁed studies complying with all ﬁve criteria as provid-
ing conﬁrmatory evidence, the presence of the ﬁnal three was
considered to provide exploratory evidence of moderation. Two or
less criteria were classiﬁed as providing insufﬁcient evidence [20].
We applied the criteria by Pincus et al. for inclusion of any trial
in a meta-analysis of moderators, that is, baseline factors should be
measured prior to randomization. Adequate quality of measure-
ment of baseline factors [20].
Risk of bias in cohort studies
Cohort studies were assessed using the QUality In Prognosis
Studies (QUIPS) tool [25]. This includes six major headings each
addressing a possible bias that could occur in a prognostic study
(study participation, study attrition, prognostic factor measure-
ment, outcome measurement, confounding, and analysis). The tool
was applied to each article in the review (using guidelines
published by the developers of the tool) and each heading was
rated as “Low,” “Moderate,” or “High” risk of bias.
Studies were judged to be of low overall risk of bias if all or
most of the domains were judged as low risk, and studies in which
all or most of the domains were judged as high risk were
considered to be of high overall risk of bias. Studies with a
moderate risk of bias were those with all or most of the domains
being judged as moderate risk of bias [25]. Differences between
reviewers were discussed and a decision made by agreement.
Data synthesis
Due to the expected heterogeneity of selected studies, we
performed a qualitative best evidence synthesis of evidence for
potential predictors from RCTs and cohort studies, taking intoaccount the strength of the association and the methodological
quality of the studies. We identiﬁed six PICO (Population, Inter-
vention, Comparator, and Outcome) questions [21] for RCTs and six
PICO questions for cohort studies to examine population features
likely to inﬂuence the effect of MMF and to assess the QoE for each
PICO question using GRADE (Grading of Recommendations,
Assessment, Development, and Evaluation) [26,27]. The PICO
comparison (C) category was not applicable and dropped for
cohort studies (Supplementary File A, Table 3). We used GRADE
approach to structure the evidence synthesis and to assess the
strength of evidence for each potential predictor/prognostic factor.
Two reviewers (C.M.P. and C.P.) judged how the GRADE factors—
phase of investigation, study limitations (Cochrane Collaboration’s risk
of bias tool; subgroup analyses; QUIPS), inconsistency, indirectness,
imprecision, publication bias, and moderate or large effect size—
impacted the overall QoE (Supplementary File A, Tables 4 and 5).
The level of evidence was rated as high, moderate, low, or very low
according to the GRADE approach [28]. We used Review Manager
(RevMan) and GRADE proﬁler (GRADEpro) software to summarize the
data on interventions and to produce the GRADE proﬁle, respectively.
Potential predictors were grouped into the following six cate-
gories: sociodemographic (e.g., age and gender) biological (e.g.,
genetic), laboratory parameters measured at baseline or during the
treatment (e.g., renal function, autoantibodies, and complement),
histopathological (e.g., LN classiﬁcation) or drug-related character-
istics (e.g., concomitant HCQ use and pharmacokinetics).Results
Summary of studies selected
Our search yielded 319 articles (Fig. 1) of which 26 (seven RCTs
with six subgroups analyses and 13 cohort studies) were included
in the analysis. A full list of excluded studies and the reason for
exclusion are available (Supplementary File A, Table 6).
Study characteristics
We included analyses from seven RCTs (Table 1) [8,9,29–33]
including secondary articles with post hoc subgroup analysis and
13 cohort studies (Table 2) [34–46]. Three RCTs presented more
than one subgroup analysis, including seven separate subgroup
analyses from the Aspreva Lupus Management (ALMS) Trial
[9,11,14,47–50]. Each subgroup was analyzed separately present-
ing analysis of each moderator separately [8,9].
Five studies included participants aged 12–18 years
[8,9,31,38,43]. The follow-up duration varied across studies; rang-
ing between 6 months (24 weeks) and 36 months for RCTs and 6–
60 months for cohort studies. All RCTs and subgroup analyses
included patients with active LN. Only three cohort studies took
into account extra-renal lupus as opposed active LN alone [40–
42,45]. No RCTs or cohort studies were identiﬁed that described
the effect of pharmacogenetics polymorphisms on outcomes in SLE
patients with MMF (PICO 4).
Methodological quality of studies and evidence
Risk of bias of RCTs
The method of randomization was explicit (low risk) in four
RCTs. Allocation concealment was adequate (low risk) in ﬁve trials.
Two trials were described as double blinded (participant or out-
come assessment) and rated as low risk [9,32]; however, in one
study only researchers conducting assessments were masked
(Fig. 2) [8]. Seven trials included an intention to treat (ITT) analysis
and only one did not carry out an ITT analysis [32]. All trials had no
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Fig. 1. Study ﬂow diagram detailing the literature search.
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were adequately presented (low risk). One study declared inde-
pendent or academic funding bodies [30]. Four declared sponsor-
ship by a pharmaceutical industry company, or included an author
who declared pharmaceutical company afﬁliation and three did
not disclose study funding sources (Fig. 3).Quality of subgroup (moderation) analysis
None of the subgroup studies provided conﬁrmatory evidence;
three studies provided exploratory evidence for race and severe LN
when MMF was compared to IVC for induction; two for race and
severe LN when MMF was compared to IVC for induction therapy
in LN [11,49] and one more for race when MMF was compared to
azathioprine for maintenance therapy [9]; and four studies pro-
vided insufﬁcient data to judge quality of subgroup analyses for
age, change in laboratory parameters at 8 weeks and membranous
LN (MLN) when MMF was compared to IVC for induction therapy
in LN [14,47,50] and when MMF was compared to tacrolimus [30]
(Table 3).Risk of bias of cohort studies
The overall methodological quality of ﬁve studies was scored as
“moderate,” eight studies scored “low,” and no study was judged
as “high” quality (Supplementary File A, Table 7). In almost all
studies, measurement of prognostic factors and outcomes were
performed in a similar, valid, and reliable way for all participants,
that is, “low” to “moderate” risk of bias. Due to lack of reporting on
key characteristics of the source population (‘study participation’)
and of participants loss to follow-up (“study attrition”), bias could
not be ruled out. We were, therefore, compelled to classify studies
as “low” (n ¼ 1), “moderate” (n ¼ 7) and “high” risk (n ¼ 5) of
selection bias. The statistical analysis, model-building process or
completeness of reporting were judged to be inadequate in all
studies, resulting in “moderate” to “high” risks of bias. The
majority of the studies reviewed only presented results from
univariable analysis on the prognostic factor(s) studied
[34,35,37,38,40–42,44]. The GRADE qualitative synthesis of evi-
dence for factors analyzed in cohort studies is shown in Table 4.Summary of QoE
All RCTs that initially were considered as high QoE were
downgraded to low or very low because most included post hoc
subgroup analyses (exploratory or insufﬁcient evidence) without
interaction tests and serious to very serious risk for imprecision
due to low sample sizes (Supplementary File B and Table 4).
The QoE of the cohort studies was initially rated as moderate.
These were downgraded due to very serious limitations concern-
ing for example, description of sampling frame and recruitment,
sample size, multiple uncontrolled confounding factors, and inad-
equate description of dropouts. Inconsistency could not be
assessed, except for one prognostic factor, because only a single
study within the existing body of literature investigated speciﬁc
factors (Table 4). Almost all cohort studies were also downgraded
for lack of precision due to inadequate sample size and incom-
pleteness in reporting of results. The QoE was downgraded for
publication bias if a very small number of studies assessed the
prognostic factor of interest and only reported positive associa-
tions. The grading could not be uprated for effect size in most of
included studies due to an absence of moderate to large effect
sizes (in terms of subgroup effects or associations with outcome),
or lack of investigating a dose effect.Synthesis of evidence
Sociodemographic factors
Age and gender (PICOs 1 and 7). Two RCTs [8,9] evaluated age
using a post hoc analysis without any interaction test (Table 3)
[47] and did not show age to be a moderator of MMF responses or
adverse (Supplementary File B, PICO 1). Only one low QoE cohort
study
(n ¼ 70) found a signiﬁcant association between younger age and
the time to renal ﬂare at 24 months (Tables 4 and 5) [35].
No RCTs evaluated/reported the inﬂuence of gender on MMF
treatment response in SLE. Two cohort studies (low QoE, n ¼ 146)
[35,43] showed that gender was not associated with complete
renal response at 6 months nor the rate of renal relapse at a
median follow-up of 24 months following treatment with MMF
(Table 5).Race/ethnicity (PICO 2 and 7). Two RCTs, comparing MMF with
synthetic therapies [8,9], showed insufﬁcient or only exploratory
evidence of subgroup effects based on race/ethnicity. One
subgroup analysis (Table 3) found that MMF and IVC response
rates for induction (24 weeks) in LN were similar for Asians and
Whites, but differed in the combined ‘Other’ and Black group [11]
(Supplementary File B, PICO 2). Exploratory evidence from
subgroup analysis and serious imprecision resulted in the QoE to
be rated as “low.” Similar ﬁndings using MMF therapy were not
described in other RCTs having longer period of follow up and with
different outcomes (treatment failure and adverse events) [9].
No cohort studies reported any association of race/ethnicity
with MMF outcomes in SLE.Laboratory parameters
Baseline renal function measures (PICO 3 and 9). In one RCT,
treatment with MMF vs. IVC in patients with LN did not show a
difference in renal response, development of end-stage renal
disease, or the incidence of serious adverse events including
infections at 24 weeks [49] using poor renal function (eGFR
o 30 mL/min/1.73 m2) as a moderator. This study had a high
risk of bias as it used post hoc subgroup analyses with very serious
imprecision.
Table 1
Characteristic of RCTs
Study ID PICO Setting Population
No. of
patients Intervention
Follow-
up Predictor Outcomes
Dall'Era et al. 2011
(ALMS) [8,14]
6 International LN III, IV, V 370 MMF 3 g/day vs. IVC 0.5–1 g/m2/m 24 w Reduction in
proteinuria
Renal response
Reduction in anti-
dsDNA
Normalization of C3
and C4
Dooley et al. (ALMS) [9] 2 International LN III, IV, V 227 MMF 2 g per day vs. azathioprine
2 mg/kg/day
36 m Race Treatment failure
Mortality
Ginzler et al. 2010
(ALMS) [8,48]
5 International LN III, IV, V 370 3 g/day vs. IVC 0.5–1 g/m2/m 24 w Active LN Extra-renal manifestation
response
Isenberg et al. 2010
(ALMS) [8,11]
2 International LN III, IV, V 370 MMF 3 g/day vs. IVC 0.5–1 g/m2/m 24 w Race Renal Response
Infectious adverse events
Serious adverse events
Mortality
Mok et al. [30] 4 China LN III, IV, V 28 MMF 3 g/day vs. Tacrolimus 0.06–
0.1 mg/kg/day
6 m Pure MLN Complete renal response
Radhakrishnan et al.
2010 (US and ALMS)
[8,29,50]
4 International LN V 87 MMF 3 g/day/day vs. IVC 0.5–
1 g/m2/m
24 w Nephrotic syndrome Change in urine protein
and SCr
Renal response
Severe infections
Sundel et al. 2012
(ALMS) [8,9,47]
1 International LN III, IV, V 24 MMF 3 g/day vs. IVC 0.5–1 g/m2/m 24 w Age Renal response
Treatment failure
MMF 2 g/d vs. azathioprine 2 mg/kg/d 36 m Infectious adverse events
Serious adverse events
End-stage disease and
Mortality
Tang et al. [31]$ 3 China Crescent
LN
44 MMF 0.75–1 g twice daily vs. IVC 0.5–
0.75 g/m2/m
12 m Crescent LN Cumulative remission %
change active and
chronic lesions
Walsh et al. 2013
(ALMS) [8,49]
3 International LN III, IV, V 32 MMF 3 g/day vs. IVC 0.5–1 g/m2/m 24 w Poor kidney function Renal responseEnd-stage
renal disease
Infection
Wang et al. [33]$ 6 China NINV LN 20 MMF 0.75 or 1 g twice daily vs. IVC
0.5–0.75 g/m2/m
6 m Non-inﬂammatory
necrotizing
vasculopathy LN
Complete response
Partial response
Adverse events
Yap et al. [32]* 4 China LN V 16 MMF 0.75–1 g twice daily (starting
dose) vs. Tacrolimus 0.1–0.15 mg/kg
per day
12 m Pure MLN Complete response
Infections
#, $, and * multiple papers on partially the same cohort.
Studies are listed in alphabetical order; ALMS, Aspreva Lupus Multicenter Study; eGFR, estimated glomerular ﬁltration rate; HCQ, hydroxychloroquine; m, monthly; IVC,
intravenous cyclophosphamide; LN, lupus nephritis; MMF, mycophenolate mofetil; NINV LN, Non-inﬂammatory necrotizing vasculopathy lupus nephritis; PICO, Population,
Intervention, Comparator, Outcome (number of PICO question); RCT, randomized clinical trial; w, weeks.
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imprecision) from one retrospective cohort [43,44] indicated that
low eGFR was an independent prognostic factor for complete renal
response but not rate of renal relapse, end-stage disease or adverse
events (gastrointestinal and infections). Similarly, baseline serum
creatinine was an independent negative prognostic factor for
remission at 24 weeks in patients LN on MMF according to one
(low QoE) prospective cohort [39], but was not associated with an
increased rate of any adverse event [42]. Moreover, baseline
proteinuria was not associated with the rate of renal relapse at
12 months [44].Laboratory parameters over time (PICO 6 and 12). In one RCT,
normalization of C3/C4 (or both) and reduction in proteinuria by
425% were associated with renal response in LN patients with
MMF therapy (Supplementary File B, PICO 6). However, these
factors were also found to be predictive in patients who received
IVC [14], indicating that they were not predictors of differential
treatment response (moderators), but were prognostic factors
regardless of type of treatment received. Reduction in anti–
double-stranded DNA (anti-dsDNA) by week 8 did not predict
renal response in the same study (to either drug).A very low QoE prospective cohort showed that persistently
elevated anti-dsDNA titers after complete renal response (CRR)
was associated with reduced time to renal ﬂare; however, persis-
tent hypocomplementaemia was not [35] (Table 5). Improvement
in serum albumin levels was found to be associated with the time
to CRR in the same cohort [35] and proteinuria at 6 months had a
signiﬁcantly negative impact on IgG level but supported by very
low QoE [46] (Table 5).Histopathological factors (PICO 4 and 10)
Three post hoc subgroup analyses from 2 RCTs [8,29,30] (very
low QoE), two reported in one publication [50] and one speciﬁc
RCT for MLN [32] did not ﬁnd signiﬁcant differences in response
rates, percent change urine protein, serum creatinine or severe
infections between MMF therapy and comparator treatments
(tacrolimus and IVC) in patients with MLN and nephrotic-range
proteinuria (Supplementary ﬁle B, PICO 4).
Two RCTs (very low QoE) did not show difference in renal
response or side effects between MMF and IVC at 6 months in
patients having either crescentic LN or non-inﬂammatory necrot-
izing vasculopathy NL [31,33]. In a group of nine patients with
crescentic LN who had renal re-biopsy, it was found that the active
Table 2
Characteristics of studies on prognostic factors
Study ID Setting PICO Design
No. of
patients Dose MMF Follow-up Predictor Outcomes Adjustment for confounders
Alexander et al.
[34]
India 11 Prospective
cohort
34 1.5 g/day at entrya 12 m MPA AUC Renal response Not indicated
Adverse events
Cortes-Hernandez
et al. [35]
Spain 7 Prospective
cohort
70 1 g two times a day 24 mb Age, improvement serum albumin levels Renal response Not indicated
9 Renal relapse
10 Treatment failure
12 Persistent anti-dsDNA
Persistent Hypocomplementaemia
Histopathological classiﬁcation
MPA trough plasma concentrations
Kasitanon et al.
[36]¥
USA 11 Retrospective
cohort
29 2120.7 mg/dayb 12 m Concomitant HCQ use Complete renal remission
in MLN
Presence of
anti-dsDNA antibody
Kasitanon et al.
[37]¥
USA 10 Retrospective
cohort
29 2000 mg/day (starting dose) 12 m Mixed MLN Complete renal remission Not indicated
Laskari et al. [38] Greece 11 Retrospective
cohort
44 2 (1.2–3) g/daya 30 ma Duration of MMF Relapse No
Side effects
Lu et al. [39] China 9 Prospective
cohort
213 MMF initiated at 1.0 g/day in
patients with less than
50 kg; 1.5 g/day: 50–70 kg
and 2.0 g/day: over 70 kg
24 w Baseline serum creatinine Renal remission Not indicated
10 Pathological classiﬁcation
Mino et al. [40] Japan 11 Prospective
cohort
34 Started on 500 mg/day MMF,
and its dose was increased
by 500 mg/day a week up
to 2500 mg/day
13 ma Plasma concentration of MPA or MPAG Changes in disease
markers
Not indicated
Nannini et al. [41] USA 11 Retrospective
cohort
29 1328 mg/dayb 14.8 mb Concomitant HCQ use Disease ﬂares Not indicated
Riskalla et al. [42] USA 9 Retrospective
cohort
54 125–3000 mg/day 12.4 mb Baseline serum creatinine Side effects Not indicated
11 MMF dose
Rivera et al. [43]£ Spain 7 Retrospective
cohort
90 2 g/daya 36 ma Gender, Complete response
Infectious
Age, gender, eGFR, LN class
and proteinuria9 Poor renal function
10 Histopathological classiﬁcation
Rivera et al. [44]£ Spain 9 Retrospective
cohort
56 1 g/daya 24 m (3–108)a Gender, End-stage disease Mortality Gender, baseline eGFR,
proteinuria and LN classProteinuria
Poor renal function
Histopathological classiﬁcation
Tselios et al. [45] Canada 9 Retrospective
cohort
177 No renal group:
1350 mg/dayb
renal group:
1687.5 mg/dayb
12 m Renal involvement Extra-renal manifestation
improvement
Not indicated
Yap et al. [46]* China 11 and 12 Retrospective
cohort
46 1.870.3 g/day at 6 m and
1.2 7 0.4 g/day at 12 mb
12 m Proteinuria Circulating IgG level Proteinuria, serum creatinine,
anti-dsDNA, C3, white cell
count and lymphocyte
count at 6 m; MMF
dose/body weight
Serum creatinine,
Anti-dsDNA and C3, white cell count
lymphocyte count at 6 m
MMF dose
¥, £, and * multiple papers on partially the same cohort.
Studies are listed in alphabetical order; eGFR, estimated glomerular ﬁltration rate; HCQ, hydroxychloroquine; m, months; LN, lupus nephritis; MLN, membranous lupus nephritis; MMF, mycophenolate mofetil; MPA AUC,
mycophenolic acid area under the curve; MPAG, mycophenolic acid glucuronide; PICO, Population, Intervention, Comparator, Outcome (number of PICO question); w, weeks.
a Median.
b Mean.
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increased in both MMF and IVC groups [31].
The prognostic value of histopathological LN class in renal
response was also investigated in four cohort studies (very low
to low QoE). One cohort study (n ¼ 213) indicated that concom-
itant membranous features on biopsy was an independent prog-
nostic factor for non-remission at 24 weeks on MMF (Table 5) [39].
Three studies (n ¼ 180, very low QoE) (6–24 months follow up)
did not demonstrate signiﬁcant associations between histological
LN class and renal response [35,37,43]. Similarly, LN class was not
signiﬁcantly associated with the rate of relapse in one small cohort
(n ¼ 56) [44].Drug-related factors (PICO 11)
No RCTs evaluated this variable. Concomitant use of HCQ with
MMF was signiﬁcantly associated with renal response when
adjusted for the presence of anti-dsDNA in MLN at 12 months
(very low QoE) (n ¼ 29) [36] but this association was not
conﬁrmed for overall disease ﬂare in one study (n ¼ 29) with aFig. 3. Risk of bias graph: review authors' judgements about each risk of bias item
presented as percentages across all RTC included studies.mean time period of follow-up after starting MMF of 14.8 months
[41] (Tables 4 and 5).
The impact of length of use and dose of MMF treatment on
outcome was examined in three cohorts (very low QoE) (Tables 4
and 5). Duration of MMF treatment r18 months was associated
with relapse at long-term (median 30 months) but not associated
with side effects in one study [38]. MMF dose was not associated
with side effects including reduced IgG levels at 6 and 12 months
in two studies (n ¼ 98) [42,46].
One very low QoE study found that mycophenolic acid area
under the curve (MPA AUC Z 30 mg h L1 was associated with
renal response but not associated with side effects (infections) at
12 months [34]. MPA and MPA glucuronide (MPAG) levels in the
interquartile ranges of 0.94–2.96 and 18.6–53.7 μg/mL, respec-
tively improved clinical laboratory markers (serum creatinine,
complement fractions, and immunoglobulins) in one study (very
low QoE) [40].
Other factors (PICO 5)
Only one RCT (n ¼ 370, moderate to very low QoE) did not ﬁnd
any inﬂuence of organ/system involvement on response to MMF
vs. IVC using either the BILAG (British Isles Lupus Assessment
Group) or SELENA-SLEDAI (Safety of Estrogens in Lupus Erythe-
matosus: National Assessment version of the Systemic Lupus
Erythematosus Disease Activity Index) [48] (Supplementary
File B, PICO 5).
One retrospective cohort study (n ¼ 177 of very low QoE) also
noted that MMF had similar outcomes in refractory extra-renal
manifestations at 6 and 12 months in patients with or without
renal involvement [45].Discussion
Our systematic review summarizes the evidence on possible
predictors (moderators) of the effect of MMF treatment for SLE in
RCTs, and factors predicting for outcomes of MMF therapy in SLE
patients in cohorts studies. For the ﬁrst objective, we identiﬁed
only potential moderation by sociodemographic (race/ethnicity) of
the effect of MMF therapy on renal response in patients with active
LN [11]. Black/Hispanic population with LN were more likely to
have a renal response at 24 weeks to MMF vs. IVC in induction
therapy. This result was, however, found in only one post hoc
subgroup analysis from an RCT with serious imprecision, resulting
in low overall quality of evidence. Race/ethnicity was studied as a
potential moderator in one additional RCT comparing MMF ther-
apy vs. azathioprine therapy [9], but a moderating effect was
not found.
We found no evidence for other potential effect moderators for
response or adverse events; thus current data do not allow us to
recommend targeting interventions with MMF at these particular
groups.
Limitations in these RCTS included the lack of “a priori”
hypotheses regarding potential moderators, insufﬁcient statistical
power, and absence of interaction tests. Our review also highlights
the importance of clarifying drug-speciﬁc effects from generic
predictors of treatment response. Therefore, while it was demon-
strated that an early normalization of complement and reduction
in proteinuria independently predict renal response to therapy at
6 months [14], those ﬁndings were not exclusive for MMF but also
were seen in the control group (IVC), indicating they are likely to
be generic prognostic factors for treatment outcome in SLE and do
not indicate a speciﬁc action of one particular drug in SLE.
In observational cohorts, the qualitative synthesis according to
the GRADE approach resulted in “low” quality evidence for base-
line serum creatinine and histological LN classiﬁcation for renal
Table 3
Methodological quality of subgroup analysis
Quality appraisal for
subgroup studies
Was the
analysis
a priori?
Was selection of factors for
analysis theory/evidence
driven
Were subgroups
measured prior to
randomization?
Adequate quality of
measurement of
baseline factors?
Contains an explicit test of the
interaction between subgroup
and treatment (e.g., regression)?
Strength of
evidence
Dooley et al. (ALMS) [9]a Yes Yes N/A Unclear Yes Exploratory
DallEra et al. (ALMS) [14]a No No Yes Yes No Insufﬁcient
Isenberg et al. (ALMS) [11]a No No N/A Unclear Yes Exploratory
Mok et al. [30] No No Yes Yes No Insufﬁcient
Radhakrishnan et al. (US
and ALMS [50]a
No No Yes Yes No Insufﬁcient
Sundel et al. (ALMS) [47]a No No Yes Yes No Insufﬁcient
Walsh et al. (ALMS) [49]a No No Yes Yes Yes Exploratory
Conﬁrmatory evidence: The study fulﬁls all of the quality assessment criteria for moderator studies (a priori analysis, factors evidence driven, moderators measured prior to
randomization, adequate measurement of baseline factors and explicit test of the interaction between moderator and treatment).
Exploratory evidence: Fulﬁlling the last three quality assessment criteria.
Insufﬁcient evidence: The study did not carry out an explicit test of interaction or measurement of the subgroups was reported to take place post randomization. ALMS,
Aspreva Lupus Multicenter Study.
a Multiple papers partially the same cohort.
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sample sizes and inconsistency of study ﬁndings. Very low QoE
was noted for a range of other prognostic factors in cohort studies.
Such factors, while not being sufﬁciently robust for routine clinical
decisions making, do nevertheless raise potential hypotheses for
evaluation when planning future studies of predictors of MMF
responses.
SLE is recognized to be a heterogeneous condition and this
heterogeneity complicates the development of prognostic models.
In addition there has been limited success in drug development
such that only a small number of positive RCTs of synthetic or
biologic therapies have been reported. It is therefore not surprising
that there is a limited number of studies examining prognostic
factors for individual drugs nor that most work in this ﬁeld to date
has been post hoc, secondary analyses. For the same reasons work
to better deﬁne subsets or “strata” of patients most likely to
respond to a particular agent is urgently needed. For many drugs
such as MMF, response rates may only be 40–60% meaning that a
signiﬁcant proportion are destined not to respond or to develop
AEs. Such periods awaiting a response may contribute to new
damage, excess steroid exposure and may also affect patient
conﬁdence in any future therapy offered. As such SLE is a condition
where stratiﬁed or precision medicine has potential to deliver
better long-term outcomes through more efﬁcient selection of
patients for new treatments as well as lower overall steroid
exposure.
Our review mainly focused on clinical factors and factors
routinely available to physicians caring for SLE patients. More
detailed knowledge about the genetic and molecular mechanisms
is also required to allow us to develop more accurate prediction
models. In this context, the identiﬁcation of polymorphic enzymes
involved in MMF metabolism may be of relevance. Uridine
diphosphate glucuronosyltransferase (UGT-1A9), inosine mono-
phosphate dehydrogenase (IMPDH-1), cytochrome P450 (CYP-
2C8), and ATP-binding cassette multidrug resistance transporter
(ABC-C2) have implications for efﬁcacy and toxicity in kidney
transplant patients on MMF therapy [51–55]. We identiﬁed only
one cross-sectional study with 19 LN, which did not meet the
selection criteria, showing that clinical and demographic param-
eters were 2–4 times more important in MPA disposition than
genotypes (UGT1A7, UGT2B7, and ABCB1/MDR1 single nucleotide
polymorphisms) and explained 30–40% of the pharmacokinetic
parameters [56]. Clearly more detailed phenotyping of patients as
well as a better understanding at a molecular level of the
pharmacodynamics of MMF in SLE may identify novel approaches
to predicting MMF treatment responses.Strength and limitations
We reported our ﬁndings as recommended by the PRISMA
statement [23] and employed not only the Cochrane Collaboration
risk of bias tool but also a tool to assess the quality of subgroup
analyses in RCTs and the QUIPS tool for the appraisal of quality of
prognostic factor studies. We judged the QoE based on the
recommendations from the GRADE working group. We believe
that the GRADE framework applied to prognostic factor research
was valuable for assessing and transparently reporting the QoE of
the possible prognostic factors. To the best of our knowledge, this
is the ﬁrst time GRADE has been used in the evaluation of
prognostic studies in SLE.
Limitations regarding the interpretation of the results from this
study should be taken into consideration. The high variability in
prognostic factors and outcomes evaluated as well as in statistical
measures and data reported made it impossible to conduct a meta-
analysis of study results. It is possible that we have missed studies
that are not indexed for these databases, but by checking refer-
ences of included studies, we presume that no relevant articles
were missed. A total of 24 of the 28 included studies in our review
referred to patients with LN. The high number of studies concern-
ing patients with LN may affect the external validity of the results
to patients with extra-renal manifestation. Future studies assess-
ing prognostic factors for extra-renal manifestations in SLE
patients on MMF therapy are needed. Similarly, most studies
included in this systematic review were in adult populations.
Another common limitation in systematic reviews is the risk of
selective reporting of primary study results. Our review included
cohort studies on prognostic factors. Such studies harbor a high
risk that non-signiﬁcant ﬁndings are not reported or only included
in the ﬁrst (unadjusted) part of the analysis. Any non-reporting of
non-signiﬁcant results increase the risk that the ﬁndings in the
synthesis were overestimated. No attempt was made to contact
study authors to obtain individual patient-level data and carry out
a meta-analysis based on such individual patient data.
Implications for clinical practice and for future research
From clinical practice point of view, no high-quality evidence
was provided for any of the potential moderators or prognostic
factors; therefore, no deﬁnite clinical conclusion can be made
about how to identify SLE patients most likely to respond to MMF
therapy. This study is, however, of value in that it identiﬁes factors
that should be included in any future study of predictors of
response to MMF and also it underscores the need to separate
Table 4
Adapted GRADE table for narrative systematic reviews of prognostic studies
GRADE factors
Possible predictors
N
studies
N
cohorts
Univariate
analysis
Multivariate
Analysis
Phase
Study
limitations Inconsistency Indirectness Imprecision
Publication
bias
Moderate-large
effect size
Exposure-response
gradient
Overall
quality Outcomesþ 0  þ 0 
Gender [43] 1 1 0 1 0 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal response
Gender [44] 1 1 0 1 0 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal relapse or
ﬂare
Younger age at study [35] 1 1 1 0 0 1 ✕ ✓ ✓ ✕ ✕ ✓ ✕ þ Renal Relapse or
ﬂare
Baseline eGFR [43] 1 1 0 0 1 0 0 1 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal response
Baseline eGFR [44] 1 1 0 1 0 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Relapse or ﬂare
Baseline eGFR [43] 1 1 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ End-stage disease
Baseline eGFR [43] 1 1 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Side effects
Baseline serum creatinine
[39]
1 1 0 0 1 0 0 1 1 ✕ ✓ ✓ ✓ ✕ ✕ ✕ þþ Renal response
Baseline serum creatinine
[42]
1 1 0 0 1 0 0 1 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Side effects
Baseline proteinuria [44] 1 1 0 1 0 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal relapse or
ﬂare
Improvement serum
albumin levels [35]
1 1 1 0 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal response
Persistent anti-dsDNA titers
[35]
1 1 1 0 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal relapse or
ﬂare
Persistent
hypocomplementaemia
[35]
1 1 0 1 0 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal relapse or
ﬂare
Biologic factors at 6 m [46] 1 1 1 0 0 1 0 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Side effects
Active LN [45] 1 1 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Extra-renal
improvement
LN class [35,37,39,43] 4 4 0 3 1 0 1 1 1 ✕ ✕ ✓ ✕ ✓ ✓ ✕ þþ Renal response
LN class [44] 1 1 0 1 0 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal relapse or
ﬂare
Concomitant HCQ use [36] 1 1 1 0 0 1 0 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal response
Concomitant HCQ use [41] 1 1 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Overall relapse or
ﬂare
Duration of MMF [38] 1 1 1 0 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal relapse or
ﬂare
MPA AUC [34] 1 1 1 0 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Renal response
MPA AUC [34] 1 1 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Side effects
Plasma concentration of
MPA [40]
1 1 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Changes in disease
markers
Plasma concentration of
MPAG [40]
1 1 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Changes in disease
markers
MPA trough plasma
concentration [34]
1 1 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Side effects
MMF dose [42,46] 2 2 0 2 0 0 1 0 1 ✕ ✓ ✓ ✕ ✕ ✕ ✕ þ Side effects
Phase, phase of investigation: phase 1 explanatory study, identifying associations; phase 2 explanatory study, testing independent associations; phase 3 explanatory study, understanding prognostic pathways.
For uni- and multivariate analyses: þ , number of signiﬁcant effects with a positive value; 0, number of non-signiﬁcant effects; and  , number of signiﬁcant effects with a negative value.
For GRADE factors: ✓, no serious limitations; ✕, serious limitations (or not present for moderate/large effect size, dose effect); unclear, unable to rate item based on available information. For overall quality of evidence: þ , very low;
þþ, low; þþþ , moderate; þþþþ, high.
Abbreviations: eGFR, estimated glomerular ﬁltration rate; GRADE, grading of recommendations assessment, development and evaluation; HCQ, hydroxychloroquine; MPA AUC, mycophenolic acid area under the curve.
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Table 5
Prognostic factors related to outcome measures
Prognostic factor No. of participants Statistical analysis Strength of association Quality score
Level of evidence Considered
judgement
Outcome: overall response or remission or improvement
Histopathological factors
Active LN 1 [45] (177) Logistic regression Patient with musculoskeletal
manifestation and renal
involvement had higher risk to have
improvement
compared to those with
non-renal involvement (RR ¼ 1.3571;
95% CI: 1.03–1.77;
P ¼ 0.025).
“Very low” evidence There is “very low” evidence that
renal involvement is not
associated with non-renal
manifestations improvement.
For other non-renal manifestations
(skin, hematological, CNS, and
serositis) were not signiﬁcant.
Outcome: Overall relapse or ﬂares
Drug-related factors
Concomitant
HCQ use
1 [41] (n ¼ 29) Person year methods Not signiﬁcant. “Very low” evidence There is “very low” evidence that
concomitant HCQ use is not
associated with disease ﬂares.
Outcome: Renal response or remission
Socio-demographic factors
Gender 1 [43] (n ¼ 90) Logistic regression
(Cox proportional hazards)
Not signiﬁcant. “Very low” evidence There is “very low” evidence that
gender is not associated with
complete renal response.
Biochemical factors
Baseline eGFR 1 [43] (n ¼ 90) Logistic regression
(Cox proportional hazards)
eGFR was an independent risk
factor (HR ¼ 2.3; 95% CI:
1.2–4.4; P ¼ 0.007).
“Very low” evidence There is “very low” evidence that
eGFR at baseline is associated
with complete renal response.
Baseline serum
creatinine
1 [39] (n ¼ 213) Logistic regression
(Cox proportional hazards
Baseline serum creatinine was
independent risk factors for not
remission (OR ¼ 1.007; 95% CI:
1.002–1.011, P ¼ 0.001).
“Low” evidence There is “low” evidence that
baseline serum creatinine is
associated with renal
remission.
Improvement
serum albumin
levels
1 [35] (n ¼ 70) Cox regression analysis Time to CR was associated with
improvement in serum
albumin levels (HR ¼ 1.12; 95% CI:
1.03–1.22; P ¼ 0.011).
“Very low” evidence There is “very low” evidence that
improvement serum albumin is
associated with complete renal
response.
Histopathological factors
LN class 1[39] (n ¼ 213)a x2 for categorical or Fisher's
exact test [37]
Not signiﬁcant [35,37,43]. “Low” evidence There is “low” evidence that
histopathological classiﬁcation
of LN is associated with renal
remission.
3 [35,37,43] (n ¼ 180)b z test for differences in
proportions when
comparing two groups [35]
Pathological classiﬁcation
(concomitant membranous
features on biopsy) is independent
risk factor for not remission (OR ¼
2.967; 95% CI: 1.479–6.332; P ¼
0.001) [39].
[39,43]Logistic regression
(Cox proportional
hazards)
Drug-related factors
Concomitant
HCQ use
1 [36] (n ¼ 29) Cox proportional
hazards model
There is an association between
concomitant HCQ use and
complete renal remission (P ¼
0.026).
“Very low” evidence There is “very low” evidence that
concomitant HCQ use is
associated with a complete
renal remission in MLN.
C.M
endoza-Pinto
et
al./
Sem
inars
in
A
rthritis
and
R
heum
atism
]
(2017)
]]]–
]]]
10
MPA AUC 1 [34] (n ¼ 34) Logistic regression
analyses
Patients with MPA AUC Z30 mg h L1
at entry had a
greater chance of achieving renal
response at 1 year (P ¼ 0.057).
“Very low” evidence There is “very low” evidence that
a MPA AUC Z30 mg h L1 is
associated with renal response.
Outcome: renal relapse or ﬂare
Socio-demographic factors
Age at study
inclusion
1 [35] (n ¼ 70) Cox regression models Younger patients HR ¼ 0.36; 95% CI:
0.14–0.90, P ¼ 0.029.
“Very low” evidence There is “low” evidence that to be
a younger patient is associated
with the time to renal ﬂare.
Gender 1 [44] (n ¼ 56) Logistic regression
(Cox proportional hazards)
Not signiﬁcant. “Very low” evidence There is “very low” evidence that
gender is not associated with
the rate of renal relapse.
Biochemical factors
Baseline eGFR 1 [44] (n ¼ 56) Logistic regression (Cox
proportional hazards)
Not signiﬁcant. “Very low” evidence There is “very low” evidence that
eGFR is not associated with the
rate of renal relapse.
Proteinuria 1 [44] (n ¼ 56) Logistic regression (Cox
proportional hazards)
Not signiﬁcant. “Very low” evidence There is “very low” evidence that
proteinuria is not associated
with the rate of renal relapse.
Persistent anti-
dsDNA titers
1 [35] (n ¼ 70) Cox regression models HR ¼ 1.001; 95% CI: 1.001–1.003; P ¼
0.005.
“Very low” evidence There is “very low” evidence that
persistent anti-dsDNA titers are
associated with the time to
renal ﬂare.
Persistent
hypocomple-
mentaemia
1 [35] (n ¼ 70) Cox regression models Not signiﬁcant. “Very low” evidence There is “very low” evidence that
persistent
hypocomplementaemia is not
associated with the time to
renal ﬂare.
Histopathological factors
Histopathologi-
cal
classiﬁcation
1 [44] (n ¼ 56) Logistic regression (Cox
proportional hazards)
Not signiﬁcant. “Very low” evidence There is “very low” evidence that
histopathological classiﬁcation
is not associated with the rate
of renal relapse.
Drug-related factors
Duration of
MMF r 18
months
after remission
1 [38] (n ¼ 44) Cox regression models Univariate analysis HR ¼ 6.85; 95% CI:
2.21–21.22; P ¼ 0.001.
“Very low” evidence There is “very low” evidence that
duration of MMF r 18 months
is associated with relapse.
Outcome: end-stage renal disease
Clinical characteristics
Baseline eGFR 1 [44] (n ¼ 70) Unpaired t-test or
Mann–Whitney test
Not signiﬁcant. “Very low” evidence There is “very low” evidence that
baseline eGFR is not associated
with end-stage renal disease.
Outcome: change in disease markers
Drug-related factors
Plasma
concentration
of MPA
1 [40] (n ¼ 31) Spearman's rank correlation
test
The ratio of the last follow-up IgA level
to that at the start of MMF correlated
signiﬁcantly (ρ ¼ 0.52, P ¼ 0.02).
“Very low” evidence There is “very low” evidence that
plasma concentration of MPA
baseline is associated with
changes of disease markers.Other markers did not correlate
signiﬁcantly.
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Table 5 (continued )
Prognostic factor No. of participants Statistical analysis Strength of association Quality score
Level of evidence Considered
judgement
Plasma
concentration
of MPAG
1[40] (n ¼ 31) Spearman's rank correlation
test
The ratios of the last follow-up C4, IgG,
and serum concentration of albumin
levels to that at the start of MMF also
correlated signiﬁcantly (ρ ¼ 0.41, P ¼
0.03; ρ ¼ 0.46, P ¼ 0.03; and ρ ¼
0.43, P ¼ 0.02).
There is “very low” evidence that
plasma concentration of MPAG
baseline is associated with
changes of disease markers.
Serum creatinine correlated
signiﬁcantly (ρ ¼ 0.58, P o 0.01).
Outcome: side effects
Clinical characteristics
Baseline serum
creatinine
1 [42] (n ¼ 54) Logistic regression Not signiﬁcant. “Very low” evidence There is ‘very low’ evidence that
baseline serum creatinine is
not associated with side effects.
Baseline eGFR 1 [43] (n ¼ 90) Unpaired t-test or Mann–
Whitney test
Not signiﬁcant. “Very low” evidence There is ‘very low’ evidence that
baseline eGFR is not associated
with side effects
(gastrointestinal and
infections).
Biologic factors
within the ﬁrst
6 months of
treatment
1 [46] (n ¼ 46) Multiple linear regression
(adjusting for class of LN
and use of pulse CTS, RASI,
and HCQ)
Proteinuria at 6 m had a signiﬁcantly
negative impact on IgG level (β ¼
1.409, P ¼ 0.028).
“Very low” evidence There is “very low” evidence that
proteinuria at 6 m is associated
with side effects (reduced IgG
levels).Other biologic factors (serum
creatinine, anti-dsDNA, C3, white
cells count and lymphocyte count)
not signiﬁcant.
Duration of
MMF
1 [38] (n ¼ 44) Binary logistic regression Not signiﬁcant. “Very low” evidence There is “very low” evidence that
duration of therapy is not
associated with side effects.
MPA AUC 1 [34] (n ¼ 34) Logistic regression analyses Not signiﬁcant. “Very low” evidence There is “very low” evidence that
MPA AUC is not associated with
side effects (infections).
MPA trough
plasma
concentrations
1 [34] (n ¼ 34) Logistic regression analyses Not signiﬁcant. “Very low” evidence There is “very low” evidence that
MPA trough plasma
concentrations are not
associated with side effects
(infections).
MMF dose 2 [42,46]
(n ¼ 98)
Multiple linear regression
(adjusting for class of LN
and use of pulse CTS, RASI,
and HCQ) [42]
Not signiﬁcant. “Very low” evidence There is “very low” evidence that
MMF dose is not associated
with side effects.
Linear regression [46]
Abbreviations: CI, conﬁdence interval; CR, complete response; CTS, corticosteroids; eGFR, estimated glomerular ﬁltration rate; GRADE, grading of recommendations assessment, development and evaluation; HCQ,
hydroxychloroquine; HR, hazard ratio; m, months; MMF, mycophenolate mofetil; MNL, membranous lupus nephritis; MPA AUC, mycophenolic acid area under the curve; MPAG, mycophenolic acid glucuronide; RASI, renin-
angiotensin system inhibitor.
a Signiﬁcant association reported number of studies (participants).
b Not signiﬁcant association reported number of studies (participants).
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that are drug speciﬁc.
Future studies on prognostic factors in SLE patients on MMF
therapy should be conducted as large, prospective, registered, and
protocol-based prognostic factor studies with sufﬁcient study
populations and transparent reporting of all factors studied. Next,
the effectiveness of stratiﬁed MMF therapy targeting speciﬁc SLE
patient subgroups based on their prognostic proﬁles should be
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